Home
Issues
2018
April 2018, Vol 7, No 1
2017
December 2017, Vol 6, No 5
October 2017, Vol 6, No 4
August 2017, Vol 6, No 3
June 2017, Vol 6, No 2
April 2017, Vol 6, No 1
2016
December 2016, Vol 5, No 6
October 2016, Vol 5, No 5
August 2016, Vol 5, No 4
June 2016, Vol 5, No 3
April 2016, Vol 5, No 2
February 2016, Vol 5, No 1
Issues Archive
Supplements
Categories
Web Exclusives
All Web Exclusives
FDA Approvals, News & Updates
In The News
Online First
Videos
About
About VBCR
About Engage HC
Contact Us
Editorial/Publishing Policies
Editorial Board
Advertising Contacts
Advertising Policy
Author Guidelines
Friday, 29 March 2024
Authored Items
Xtampza ER, an Oxycodone Analgesic with Abuse-Deterrent Properties, Approved for the Treatment of Patients with Chronic Pain
Lisa A. Raedler, PhD, RPh
VBCN - November 2016 Volume 3, No 3
in
Drug Updates
Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple Myeloma
Lisa A. Raedler, PhD, RPh
VBCC - May 2016, Vol 7, No 4
in
Drug Updates
Fycompa (Perampanel Hydrate) Receives Expanded Indication for Primary Tonic-Clonic Seizures
Lisa A. Raedler, PhD, RPh
VBCN - April 2016 Volume 3, No 1
in
Drug Updates
Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Lisa A. Raedler, PhD, RPh
VBCC - April 2016, Vol 7, No 3
in
Drug Updates
Onivyde (Irinotecan Liposome Injection) a New Treatment Option for Patients with Metastatic Pancreatic Cancer
Lisa A. Raedler, PhD, RPh
VBCC - March 2016, Vol 7, No 2
in
Drug Updates
,
Online First
Keytruda (Pembrolizumab) First PD-1 Inhibitor Approved for the Treatment of Patients with Metastatic Non–Small-Cell Lung Cancer Expressing PD-L1
Lisa A. Raedler, PhD, RPh
VBCC - December 2015, Vol 6, No 11
in
Drug Updates
Ibrance (Palbociclib): First CDK4 and CDK6 Inhibitor FDA Approved for the Treatment of Postmenopausal Women with Metastatic Breast Cancer
Lisa A. Raedler, PhD, RPh
VBCC - August 2015, Vol 6, No 7
in
Drug Updates
Farydak (Panobinostat): First HDAC Inhibitor Approved for the Treatment of Patients with Relapsed Multiple Myeloma
Lisa A. Raedler, PhD, RPh
VBCC - July 2015, Vol 6, No 6
in
Drug Updates
Jakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera
Lisa A. Raedler, PhD, RPh
VBCC - June 2015, Vol 6, No 5
in
Drug Updates
Nivolumab (Opdivo): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma
Lisa A. Raedler, PhD, RPh
VBCC - February 2015, Vol 6, No 1
in
Drug Updates
Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for Previously Treated Unresectable or Metastatic Melanoma
Lisa A. Raedler, PhD, RPh
VBCC - December 2014, Vol 5, No 10
in
Drug Updates
Zydelig (Idelalisib): First-in-Class PI3 Kinase Inhibitor Approved by the FDA for the Treatment of 3 Hematologic Malignancies
Lisa A. Raedler, PhD, RPh
VBCC - November 2014, Vol 5, No 9
in
Drug Updates
Beleodaq (Belinostat) Receives FDA Approval for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
Lisa A. Raedler, PhD, RPh
VBCC - October 2014, Vol 5, No 8
in
Drug Updates
Arzerra (Ofatumumab) Receives FDA Approval for Patients with Previously Untreated Chronic Lymphocytic Leukemia for Use in Combination with Chlorambucil
Lisa A. Raedler, PhD, RPh
VBCC - September 2014 Vol 5, No 7
in
Drug Updates
Zykadia (Ceritinib) Approved for the Treatment of Patients with Crizotinib-Resistant ALK-Positive Non–Small-Cell Lung Cancer
Lisa A. Raedler, PhD, RPh
VBCC - August 2014 Vol 5, No 6
in
Drug Updates
Imbruvica (Ibrutinib) the First Bruton’s Tyrosine Kinase Inhibitor Approved for Treatment of Patients with Relapsed Chronic Lymphocytic Leukemia
Lisa A. Raedler, PhD, RPh
VBCC - May 2014 Vol 5, No 4
in
Drug Updates
Gazyva for Chronic Lymphocytic Leukemia: First FDA-Approved Breakthrough Therapy in Oncology
Lisa A. Raedler, PhD, RPh
VBCC - March 2014, Volume 5, No 2
in
Drug Updates
Abraxane Receives a New Indication for the Treatment of Patients with Metastatic Pancreatic Cancer
Lisa A. Raedler, PhD, RPh
VBCC - February 2014, Volume 5, No 1
in
Drug Updates
Otrexup Injection: Novel Methotrexate Delivery System for Patients with Rheumatoid Arthritis
Lisa A. Raedler, PhD, RPh
VBCR - February 2014, Volume 3, No 1
in
Drug Updates
Gilotrif: Second-Generation Tyrosine Kinase Inhibitor Indicated for the First-Line Treatment of Patients with Non–Small-Cell Lung Cancer and EGFR Mutation
Lisa A. Raedler, PhD, RPh
VBCC - November 2013, Volume 4, No 9
in
Drug Updates
Revlimid Receives a New Indication for the Treatment of Patients with Relapsed or Progressing Mantle-Cell Lymphoma
Lisa A. Raedler, PhD, RPh
VBCC - October 2013, Volume 4, No 8
in
Drug Updates
Tafinlar and Mekinist: Two Oral Targeted Kinase Inhibitors for the Treatment of Patients with Metastatic Melanoma and BRAF Mutations
Lisa A. Raedler, PhD, RPh
VBCC - September 2013, Volume 4, No 7
in
Drug Updates
Xofigo (Radium Ra 223 Dichloride): The First Alpha Particle–Emitting Radioactive Agent for the Treatment of Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases
Lisa A. Raedler, PhD, RPh
VBCC - July 2013, Volume 4, No 6
in
Drug Updates
Kadcyla (Ado-Trastuzumab Emtansine): First Antibody-Drug Conjugate Approved for the Treatment of HER2-Positive Metastatic Breast Cancer
Lisa A. Raedler, PhD, RPh
VBCC - June 2013, Volume 4, No 5
in
Drug Updates
Global Perspectives on the Economics of Cancer Care
Lisa A. Raedler, PhD, RPh
VBCM - Meeting Highlights
in
EHA 2013
Last modified: June 19, 2013
Home
Issues
2018
April 2018, Vol 7, No 1
2017
December 2017, Vol 6, No 5
October 2017, Vol 6, No 4
August 2017, Vol 6, No 3
June 2017, Vol 6, No 2
April 2017, Vol 6, No 1
2016
December 2016, Vol 5, No 6
October 2016, Vol 5, No 5
August 2016, Vol 5, No 4
June 2016, Vol 5, No 3
April 2016, Vol 5, No 2
February 2016, Vol 5, No 1
Issues Archive
Supplements
Categories
Web Exclusives
All Web Exclusives
FDA Approvals, News & Updates
In The News
Online First
Videos
About
About VBCR
About Engage HC
Contact Us
Editorial/Publishing Policies
Editorial Board
Advertising Contacts
Advertising Policy
Author Guidelines